EU/3/18/1991: Orphan designation for the treatment of sickle cell disease

Docosahexaenoic acid ethyl ester


On 21 March 2018, orphan designation (EU/3/18/1991) was granted by the European Commission to TurnKey PharmaConsulting Ireland Limited, Ireland, for docosahexaenoic acid ethyl ester (also known as SC411) for the treatment of sickle cell disease.

Key facts

Active substance
Docosahexaenoic acid ethyl ester
Intended use
Treatment of sickle cell disease
Orphan designation status
EU designation number
Date of designation

Turnkey PharmaConsulting Ireland Limited
Ellerman House
Cratloe Wood
County Clare
Tel. + 353 86 844 6816

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating